Literature DB >> 32082469

Langerhans Cell Histiocytosis with Isolated Cutaneous Involvement Refractory to Polychemotherapy: A Case Report.

Francisco Javier Lira-Valero1, Nancy Pulido-Díaz1, Marissa De Jesús Quintal-Ramírez1.   

Abstract

BACKGROUND: Langerhans cell histiocytosis (LCH) is a neoplasm of the monocyte-macrophage lineage, characterized by clonal proliferation and dissemination of cells that express CD1a+ and CD207. It is a disorder that predominates in childhood. Although the skin is the second most frequently affected organ (30-60%), isolated cutaneous involvement is rare; its frequency does not exceed 4 to 12 percent of cases. Single system-LCH usually has a good prognosis. We describe a case of LCH with isolated cutaneous involvement that presented in an adult patient and was refractory to polychemotherapy.
Copyright © 2020. Matrix Medical Communications. All rights reserved.

Entities:  

Keywords:  Langerhans cell; cutaneous; histiocytosis

Year:  2020        PMID： 32082469      PMCID： PMC7028377     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN： 1941-2789


  9 in total

1.  New insights into the molecular pathogenesis of langerhans cell histiocytosis.

Authors:  Francesca M Rizzo; Mauro Cives; Valeria Simone; Franco Silvestris
Journal:  Oncologist       Date:  2014-01-16

Review 2.  Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Authors:  Jean-François Emile; Oussama Abla; Sylvie Fraitag; Annacarin Horne; Julien Haroche; Jean Donadieu; Luis Requena-Caballero; Michael B Jordan; Omar Abdel-Wahab; Carl E Allen; Frédéric Charlotte; Eli L Diamond; R Maarten Egeler; Alain Fischer; Juana Gil Herrera; Jan-Inge Henter; Filip Janku; Miriam Merad; Jennifer Picarsic; Carlos Rodriguez-Galindo; Barret J Rollins; Abdellatif Tazi; Robert Vassallo; Lawrence M Weiss
Journal:  Blood       Date:  2016-03-10       Impact factor: 22.113

3.  Cutaneous Langerhans cell histiocytosis: study of Asian children shows good overall prognosis.

Authors:  Shanna Shan-Yi Ng; Mark Jean-Aan Koh; Yong-Kwang Tay
Journal:  Acta Paediatr       Date:  2013-09-02       Impact factor: 2.299

4.  Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome.

Authors:  D M Howarth; G S Gilchrist; B P Mullan; G A Wiseman; J H Edmonson; P J Schomberg
Journal:  Cancer       Date:  1999-05-15       Impact factor: 6.860

5.  Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan.

Authors:  Akira Morimoto; Yasushi Ishida; Nobuhiro Suzuki; Shouichi Ohga; Yoko Shioda; Yuri Okimoto; Kazuko Kudo; Eiichi Ishii
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

Review 6.  Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies.

Authors:  Caroline Hutter; Milen Minkov
Journal:  Immunotargets Ther       Date:  2016-10-12

Review 7.  Langerhans cell histiocytosis in children - a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment.

Authors:  Michalina Jezierska; Joanna Stefanowicz; Grzegorz Romanowicz; Wojciech Kosiak; Magdalena Lange
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

Review 8.  Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net.

Authors:  Michael Girschikofsky; Maurizio Arico; Diego Castillo; Anthony Chu; Claus Doberauer; Joachim Fichter; Julien Haroche; Gregory A Kaltsas; Polyzois Makras; Angelo V Marzano; Mathilde de Menthon; Oliver Micke; Emanuela Passoni; Heinrich M Seegenschmiedt; Abdellatif Tazi; Kenneth L McClain
Journal:  Orphanet J Rare Dis       Date:  2013-05-14       Impact factor: 4.123

9.  Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.

Authors:  Riccardo Haupt; Milen Minkov; Itziar Astigarraga; Eva Schäfer; Vasanta Nanduri; Rima Jubran; R Maarten Egeler; Gritta Janka; Dragan Micic; Carlos Rodriguez-Galindo; Stefaan Van Gool; Johannes Visser; Sheila Weitzman; Jean Donadieu
Journal:  Pediatr Blood Cancer       Date:  2012-10-25       Impact factor: 3.167
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.